Treatment of Low-Blast Count AML using Hypomethylating Agents.

about

Treatment of Low-Blast Count AML using Hypomethylating Agents.

Item

http://www.wikidata.org/entity/Q39429687

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh

2017年學術文章

@zh-hant

name

Treatment of Low-Blast Count AML using Hypomethylating Agents.

@en

Treatment of Low-Blast Count AML using Hypomethylating Agents.

@nl

type

Item

label

Treatment of Low-Blast Count AML using Hypomethylating Agents.

@en

Treatment of Low-Blast Count AML using Hypomethylating Agents.

@nl

prefLabel

Treatment of Low-Blast Count AML using Hypomethylating Agents.

@en

Treatment of Low-Blast Count AML using Hypomethylating Agents.

@nl

P1476

Treatment of Low-Blast Count AML using Hypomethylating Agents.

@en

P2093

Ambra Di Veroli

http://www.w3.org/2001/XMLSchema#string

Eleonora De Bellis

http://www.w3.org/2001/XMLSchema#string

Francesco Lo-Coco

http://www.w3.org/2001/XMLSchema#string

Laura Cicconi

http://www.w3.org/2001/XMLSchema#string

Luca Maurillo

http://www.w3.org/2001/XMLSchema#string

Maria Ilaria Del Principe

http://www.w3.org/2001/XMLSchema#string

Mattia Brescini

http://www.w3.org/2001/XMLSchema#string

Sergio Amadori

http://www.w3.org/2001/XMLSchema#string

William Arcese

http://www.w3.org/2001/XMLSchema#string

P2860

Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study

The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia.

The blockade of immune checkpoints in cancer immunotherapy

The World Health Organization (WHO) classification of the myeloid neoplasms

Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study

International scoring system for evaluating prognosis in myelodysplastic syndromes

Multicenter, randomized, open-label, phase III trial of decitabine versus patient choice, with physician advice, of either supportive care or low-dose cytarabine for the treatment of older patients with newly diagnosed acute myeloid leukemia.

Expression of PD-L1, PD-L2, PD-1 and CTLA4 in myelodysplastic syndromes is enhanced by treatment with hypomethylating agents.

Interactions and relevance of blast percentage and treatment strategy among younger and older patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS)

Clinical response and miR-29b predictive significance in older AML patients treated with a 10-day schedule of decitabine.

P304

e2017045

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.4084/MJHID.2017.045

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

P577

2017-07-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28698788

http://www.w3.org/2001/XMLSchema#string

P932

5499495

http://www.w3.org/2001/XMLSchema#string